BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C, Perdrix A, Paresy M, Antonietti M, Iwanicki-Caron I. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017;117:1017-1025. [PMID: 28772284 DOI: 10.1038/bjc.2017.250] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 DiPardo BJ, Winograd P, Court CM, Tomlinson JS. Pancreatic cancer circulating tumor cells: applications for personalized oncology. Expert Rev Mol Diagn 2018;18:809-20. [PMID: 30099926 DOI: 10.1080/14737159.2018.1511429] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
2 Abdallah R, Taly V, Zhao S, Pietrasz D, Bachet JB, Basile D, Mas L, Zaanan A, Laurent-Puig P, Taieb J. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Cancer Treat Rev 2020;87:102028. [PMID: 32485509 DOI: 10.1016/j.ctrv.2020.102028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Mamdouhi T, Twomey JD, McSweeney KM, Zhang B. Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases. Cancer Metastasis Rev 2019;38:297-305. [PMID: 31053984 DOI: 10.1007/s10555-019-09795-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
4 Luchini C, Veronese N, Nottegar A, Cappelletti V, Daidone MG, Smith L, Parris C, Brosens LAA, Caruso MG, Cheng L, Wolfgang CL, Wood LD, Milella M, Salvia R, Scarpa A. Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. Cancers (Basel) 2019;11:E1152. [PMID: 31405192 DOI: 10.3390/cancers11081152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
5 Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pellè E, Quaresmini D, Tucci M, Silvestris F. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol 2018;10:1758835918794630. [PMID: 30181785 DOI: 10.1177/1758835918794630] [Cited by in Crossref: 149] [Cited by in F6Publishing: 136] [Article Influence: 37.3] [Reference Citation Analysis]
6 Konno N, Suzuki R, Takagi T, Sugimoto M, Asama H, Sato Y, Irie H, Hikichi T, Ohira H. Clinical utility of a newly developed microfluidic device for detecting circulating tumor cells in the blood of patients with pancreatico-biliary malignancies. J Hepatobiliary Pancreat Sci 2021;28:115-24. [PMID: 33090657 DOI: 10.1002/jhbp.850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Loft M, Lee B, Tie J, Gibbs P. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. J Pers Med 2019;9:E37. [PMID: 31323810 DOI: 10.3390/jpm9030037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Yamamoto Y, Uemura M, Fujita M, Maejima K, Koh Y, Matsushita M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, Kinouchi T, Hayashi T, Matsuzaki K, Jingushi K, Kato T, Kawashima A, Ujike T, Nagahara A, Fujita K, Imamura R, Nakagawa H, Nonomura N. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. Cancer Sci 2019;110:617-28. [PMID: 30536551 DOI: 10.1111/cas.13906] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
9 Buscail E, Maulat C, Muscari F, Chiche L, Cordelier P, Dabernat S, Alix-Panabières C, Buscail L. Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2019;11:E852. [PMID: 31248203 DOI: 10.3390/cancers11060852] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 8.7] [Reference Citation Analysis]
10 Koessler T, Addeo A, Nouspikel T. Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual. Adv Clin Chem 2019;89:131-88. [PMID: 30797468 DOI: 10.1016/bs.acc.2018.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chen X, Liu F, Xue Q, Weng X, Xu F. Metastatic pancreatic cancer: Mechanisms and detection (Review). Oncol Rep 2021;46:231. [PMID: 34498718 DOI: 10.3892/or.2021.8182] [Reference Citation Analysis]
12 Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers (Basel) 2021;13:1986. [PMID: 33924143 DOI: 10.3390/cancers13081986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Balendran-Braun S, Kieler M, Liebmann-Reindl S, Unseld M, Bianconi D, W Prager G, Streubel B. Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing. Cancer Manag Res 2021;13:6249-61. [PMID: 34393517 DOI: 10.2147/CMAR.S308029] [Reference Citation Analysis]
14 Milin-Lazovic J, Madzarevic P, Rajovic N, Djordjevic V, Milic N, Pavlovic S, Veljkovic N, Milic NM, Radenkovic D. Meta-Analysis of Circulating Cell-Free DNA's Role in the Prognosis of Pancreatic Cancer. Cancers (Basel) 2021;13:3378. [PMID: 34298594 DOI: 10.3390/cancers13143378] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Huerta M, Roselló S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervelló C, Garcés-Albir M, Cervantes A, Ibarrola-Villava M. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cancers (Basel) 2021;13:994. [PMID: 33673558 DOI: 10.3390/cancers13050994] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Grunvald MW, Jacobson RA, Kuzel TM, Pappas SG, Masood A. Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer. Int J Mol Sci. 2020;21:7651. [PMID: 33081107 DOI: 10.3390/ijms21207651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Yee NS, Zhang S, He HZ, Zheng SY. Extracellular Vesicles as Potential Biomarkers for Early Detection and Diagnosis of Pancreatic Cancer. Biomedicines 2020;8:E581. [PMID: 33297544 DOI: 10.3390/biomedicines8120581] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
18 Khakoo S, Petrillo A, Salati M, Muhith A, Evangelista J, Seghezzi S, Petrelli F, Tomasello G, Ghidini M. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Cancers (Basel) 2021;13:4396. [PMID: 34503206 DOI: 10.3390/cancers13174396] [Reference Citation Analysis]
19 Konczalla L, Wöstemeier A, Kemper M, Karstens KF, Izbicki J, Reeh M. Clinical Significance of Circulating Tumor Cells in Gastrointestinal Carcinomas. Diagnostics (Basel) 2020;10:E192. [PMID: 32235479 DOI: 10.3390/diagnostics10040192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Takeda K, Yamada T, Takahashi G, Iwai T, Ueda K, Kuriyama S, Koizumi M, Matsuda A, Shinji S, Ohta R, Yokoyama Y, Hotta M, Hara K, Yoshida H. Analysis of colorectal cancer-related mutations by liquid biopsy: Utility of circulating cell-free DNA and circulating tumor cells. Cancer Sci 2019;110:3497-509. [PMID: 31465598 DOI: 10.1111/cas.14186] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
21 Iovanna J. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Transl Oncol 2021;14:100965. [PMID: 33248412 DOI: 10.1016/j.tranon.2020.100965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Franczak C, Filhine-Tressarieu P, Broséus J, Gilson P, Merlin JL, Harlé A. Clinical Interest of Circulating Tumor DNA in Oncology. Arch Med Res 2018;49:297-305. [PMID: 30414710 DOI: 10.1016/j.arcmed.2018.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Moati E, Taly V, Garinet S, Didelot A, Taieb J, Laurent-Puig P, Zaanan A. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. Cancers (Basel) 2021;13:4743. [PMID: 34638228 DOI: 10.3390/cancers13194743] [Reference Citation Analysis]
24 To YH, Lee B, Wong HL, Gibbs P, Tie J. Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. Visc Med 2020;36:388-96. [PMID: 33178736 DOI: 10.1159/000509657] [Reference Citation Analysis]
25 Buscail E, Alix-Panabières C, Quincy P, Cauvin T, Chauvet A, Degrandi O, Caumont C, Verdon S, Lamrissi I, Moranvillier I, Buscail C, Marty M, Laurent C, Vendrely V, Moreau-Gaudry F, Bedel A, Dabernat S, Chiche L. High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery. Cancers (Basel) 2019;11:E1656. [PMID: 31717747 DOI: 10.3390/cancers11111656] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
26 Yang Z, LaRiviere MJ, Ko J, Till JE, Christensen T, Yee SS, Black TA, Tien K, Lin A, Shen H, Bhagwat N, Herman D, Adallah A, O'Hara MH, Vollmer CM, Katona BW, Stanger BZ, Issadore D, Carpenter EL. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3248-58. [PMID: 32299821 DOI: 10.1158/1078-0432.CCR-19-3313] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
27 Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71-88. [PMID: 30410101 DOI: 10.1038/s41576-018-0071-5] [Cited by in Crossref: 363] [Cited by in F6Publishing: 344] [Article Influence: 121.0] [Reference Citation Analysis]
28 Jacobson RA, Munding E, Hayden DM, Levy M, Kuzel TM, Pappas SG, Masood A. Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers. Cancers (Basel) 2019;11:E1164. [PMID: 31412682 DOI: 10.3390/cancers11081164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
29 Laurent L, Sefrioui D, Bignon AL, Parzy A, Sidali S, Hassine M, Gangloff A, Galais MP, Bouhier-Leporrier K, Michel P, Di Fiore F. CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. HPB (Oxford) 2019;21:582-8. [PMID: 30466797 DOI: 10.1016/j.hpb.2018.09.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Al-Shaheri FN, Alhamdani MSS, Bauer AS, Giese N, Büchler MW, Hackert T, Hoheisel JD. Blood biomarkers for differential diagnosis and early detection of pancreatic cancer. Cancer Treat Rev 2021;96:102193. [PMID: 33865174 DOI: 10.1016/j.ctrv.2021.102193] [Reference Citation Analysis]
31 Liu X, Liu L, Ji Y, Li C, Wei T, Yang X, Zhang Y, Cai X, Gao Y, Xu W, Rao S, Jin D, Lou W, Qiu Z, Wang X. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer. EBioMedicine 2019;41:345-56. [PMID: 30857943 DOI: 10.1016/j.ebiom.2019.02.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
32 Zhu Y, Zhang H, Chen N, Hao J, Jin H, Ma X. Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99:e18581. [PMID: 32011436 DOI: 10.1097/md.0000000000018581] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
33 O'Neill RS, Stoita A. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J Gastroenterol 2021; 27(26): 4045-4087 [PMID: 34326612 DOI: 10.3748/wjg.v27.i26.4045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Bunduc S, Gede N, Váncsa S, Lillik V, Kiss S, Dembrovszky F, Eróss B, Szakács Z, Gheorghe C, Mikó A, Hegyi P. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2021;169:103548. [PMID: 34843928 DOI: 10.1016/j.critrevonc.2021.103548] [Reference Citation Analysis]
35 Pang TCY, Po JW, Becker TM, Goldstein D, Pirola RC, Wilson JS, Apte MV. Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. Pancreatology 2021;21:103-14. [PMID: 33309014 DOI: 10.1016/j.pan.2020.11.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Martini V, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, Kulemann B. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Cancers (Basel) 2019;11:E1659. [PMID: 31717773 DOI: 10.3390/cancers11111659] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
37 Kunovsky L, Tesarikova P, Kala Z, Kroupa R, Kysela P, Dolina J, Trna J. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. Can J Gastroenterol Hepatol 2018;2018:5389820. [PMID: 30186820 DOI: 10.1155/2018/5389820] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
38 Yang C, Xia BR, Jin WL, Lou G. Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model. Cancer Cell Int 2019;19:341. [PMID: 31866766 DOI: 10.1186/s12935-019-1067-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
39 Mathai RA, Vidya RVS, Reddy BS, Thomas L, Udupa K, Kolesar J, Rao M. Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. J Clin Med 2019;8:E373. [PMID: 30889786 DOI: 10.3390/jcm8030373] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 15.0] [Reference Citation Analysis]
40 Aoki M, Shoji H, Kashiro A, Takeuchi K, Shimizu Y, Honda K. Prospects for Comprehensive Analyses of Circulating Tumor Cells in Tumor Biology. Cancers (Basel) 2020;12:E1135. [PMID: 32369927 DOI: 10.3390/cancers12051135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
41 Wei T, Zhang X, Zhang Q, Yang J, Chen Q, Wang J, Li X, Chen J, Ma T, Li G, Gao S, Lou J, Que R, Wang Y, Dang X, Zheng L, Liang T, Bai X. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Cancer Letters 2019;452:237-43. [DOI: 10.1016/j.canlet.2019.03.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
42 Gall TMH, Belete S, Khanderia E, Frampton AE, Jiao LR. Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma. Am J Pathol 2019;189:71-81. [PMID: 30558725 DOI: 10.1016/j.ajpath.2018.03.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
43 Song BG, Kwon W, Kim H, Lee EM, Han YM, Kim H, Byun Y, Lee KB, Lee KH, Lee KT, Lee JK, Jang JY, Park JK. Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker. Front Oncol 2020;10:616440. [PMID: 33680936 DOI: 10.3389/fonc.2020.616440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
44 Kim H, Heo CM, Oh J, Chung HH, Lee EM, Park J, Lee SH, Lee KH, Lee KT, Lee JK, Cho YK, Park JK. Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma. Transl Oncol 2021;16:101321. [PMID: 34954457 DOI: 10.1016/j.tranon.2021.101321] [Reference Citation Analysis]
45 Rice A, Del Rio Hernandez A. The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA. Front Oncol 2019;9:952. [PMID: 31608239 DOI: 10.3389/fonc.2019.00952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Samandari M, Julia MG, Rice A, Chronopoulos A, del Rio Hernandez AE. Liquid biopsies for management of pancreatic cancer. Translational Research 2018;201:98-127. [DOI: 10.1016/j.trsl.2018.07.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
47 Wang ZY, Ding XQ, Zhu H, Wang RX, Pan XR, Tong JH. KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients. Front Oncol 2019;9:1295. [PMID: 31850201 DOI: 10.3389/fonc.2019.01295] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
48 Llop E, Guerrero PE, Duran A, Barrabés S, Massaguer A, Ferri MJ, Albiol-Quer M, de Llorens R, Peracaula R. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma. World J Gastroenterol 2018; 24(24): 2537-2554 [PMID: 29962812 DOI: 10.3748/wjg.v24.i24.2537] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
49 Lee JS, Park SS, Lee YK, Norton JA, Jeffrey SS. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Mol Oncol 2019;13:1623-50. [PMID: 31243883 DOI: 10.1002/1878-0261.12537] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
50 Hou J, Li X, Xie KP. Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. Mol Cancer 2021;20:34. [PMID: 33593396 DOI: 10.1186/s12943-021-01309-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Leers MPG. Circulating tumor DNA and their added value in molecular oncology. Clin Chem Lab Med 2020;58:152-61. [PMID: 31490771 DOI: 10.1515/cclm-2019-0436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]